…
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Connect Biopharma Holdings is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for immune-mediated and inflammatory diseases. Its long-term growth drivers include advancement of its clinical-stage pipeline, potential strategic partnerships, and regulatory approvals in targeted indications that may benefit patients with unmet needs. Investors may find the company attractive because successful trial readouts could materially de-risk programs and support commercial opportunities.
The primary investment risks are program-level clinical and regulatory failure combined with limited operating history and the likely need for additional financing to complete development and commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -55.28M | -15.40M | -61.99M | -795.02M | -1305.13M |
| Net income | -55.48M | -15.63M | -62.11M | -797.05M | -1306.82M |
| Selling general administrative | 20.34M | 19.23M | 16.05M | 139.44M | 122.44M |
| Selling and marketing expenses | - | - | 13.51M | - | - |
| Gross profit | 0.06M | 26.03M | -0.99M | - | - |
| Reconciled depreciation | 0.70M | 0.66M | 0.99M | 6.94M | 4.08M |
| Ebit | -58.07M | -22.45M | -69.06M | -805.59M | -631.44M |
| Ebitda | -57.37M | -21.79M | -68.34M | -762.07M | -1305.08M |
| Depreciation and amortization | 0.70M | 0.66M | 0.72M | 43.52M | -673.65M |
| Operating income | -58.07M | -22.45M | -69.06M | -805.59M | -631.44M |
| Other operating expenses | 58.14M | 48.48M | 69.06M | 785.22M | 621.47M |
| Interest expense | - | - | 0.02M | 0.14M | 0.04M |
| Tax provision | 0.20M | 0.22M | 0.12M | 2.04M | 1.70M |
| Interest income | 2.27M | 4.45M | 2.71M | 10.71M | 0.62M |
| Net interest income | 2.27M | 4.45M | 2.69M | 10.57M | 0.58M |
| Income tax expense | 0.20M | 0.22M | 0.12M | 2.04M | 1.70M |
| Total revenue | 0.06M | 26.03M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 58.14M | 48.48M | 69.06M | 785.22M | 621.47M |
| Cost of revenue | - | 0.66M | 0.99M | - | - |
| Total other income expense net | 2.79M | 7.05M | 7.07M | 10.57M | -673.69M |
| Net income from continuing ops | -55.48M | -15.63M | -59.50M | -797.05M | -1306.82M |
| Net income applicable to common shares | - | - | - | - | -1306.82M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 56.08M | 101.28M | 125.89M | 1211.93M | 1855.66M |
| Intangible assets | 0.04M | 0.05M | 0.06M | 22.04M | 22.55M |
| Other current assets | 6.43M | 2.20M | - | - | 3.95M |
| Total liab | 14.10M | 9.12M | 24.85M | 115.06M | 119.83M |
| Total stockholder equity | 41.98M | 92.17M | 101.04M | -3175.22M | 1735.83M |
| Other current liab | 11.16M | 7.80M | 3.00M | 24.39M | 32.84M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.07M | 0.07M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.07M | 0.07M |
| Retained earnings | -400.83M | -345.36M | -539.35M | -3175.22M | -2378.16M |
| Other liab | - | - | - | - | 5.00M |
| Good will | - | - | - | - | -21.99M |
| Other assets | - | - | - | - | 18.81M |
| Cash | 38.34M | 78.23M | 106.01M | 550.27M | 1706.88M |
| Total current liabilities | 13.61M | 8.46M | 24.26M | 108.82M | 114.67M |
| Current deferred revenue | 0.17M | 0.16M | 13.32M | - | - |
| Net debt | -37.66M | -78.05M | -105.54M | -547.28M | -1706.09M |
| Short term debt | 0.32M | 0.15M | 0.28M | 1.29M | 0.63M |
| Short long term debt total | 0.69M | 0.18M | 0.47M | 3.00M | 0.79M |
| Other stockholder equity | 444.00M | 439.18M | 648.26M | -71.19M | 4155.17M |
| Property plant equipment | - | - | - | - | 82.16M |
| Total current assets | 50.93M | 96.96M | 120.97M | 1084.94M | 1754.13M |
| Long term investments | - | - | 0.00M | 65.74M | - |
| Net tangible assets | - | - | - | - | 1735.27M |
| Short term investments | 6.00M | 15.48M | 12.65M | 511.25M | 0.00M |
| Net receivables | 0.16M | 1.05M | 0.18M | 1.61M | 47.26M |
| Accounts payable | 1.96M | 0.34M | 7.66M | 83.14M | 81.19M |
| Accumulated other comprehensive income | -1.19M | -1.67M | -7.88M | 71.12M | -41.24M |
| Non currrent assets other | 0.65M | 0.03M | 0.13M | 0.24M | 18.81M |
| Non current assets total | 5.15M | 4.32M | 4.92M | 126.99M | 101.52M |
| Capital lease obligations | 0.69M | 0.18M | 0.47M | 3.00M | 0.79M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 10.25M | -3.45M | 75.16M | -571.31M | 13.50M |
| Change to liabilities | - | - | - | - | 56.60M |
| Total cashflows from investing activities | 9.82M | -3.45M | 75.16M | - | -34.02M |
| Net borrowings | - | - | -0.29M | - | -0.81M |
| Total cash from financing activities | 1.09M | 0.23M | -0.25M | -0.62M | 1316.10M |
| Change to operating activities | - | - | - | - | -19.66M |
| Net income | -55.48M | -15.63M | -59.38M | -795.02M | -1305.13M |
| Change in cash | -39.89M | -27.43M | 27.00M | -1156.61M | 696.80M |
| Begin period cash flow | 78.23M | 105.66M | 79.01M | 1706.88M | 1010.08M |
| End period cash flow | 38.34M | 78.23M | 106.01M | 550.27M | 1706.88M |
| Total cash from operating activities | -51.21M | -23.61M | -47.93M | -679.66M | -544.93M |
| Issuance of capital stock | - | - | 0.04M | 0.13M | 1431.78M |
| Depreciation | 0.70M | 0.66M | 0.99M | 6.94M | 4.08M |
| Other cashflows from investing activities | 0.78M | 0.12M | -0.08M | - | -22.28M |
| Dividends paid | - | - | - | - | 0.24M |
| Change to account receivables | 0.78M | -0.79M | 1.04M | - | -16.12M |
| Sale purchase of stock | - | - | 0.00M | 0.00M | -3.67M |
| Other cashflows from financing activities | 1.09M | 0.23M | 75.16M | 0.76M | -110.95M |
| Change to netincome | - | - | - | - | 737.00M |
| Capital expenditures | 0.43M | 0.75M | 0.29M | 29.32M | 47.53M |
| Change in working capital | 0.58M | -15.49M | 9.48M | 49.02M | 20.82M |
| Stock based compensation | 3.73M | 6.73M | 3.26M | 45.60M | 57.86M |
| Other non cash items | -0.74M | 0.12M | -2.28M | -9.25M | 0.04M |
| Free cash flow | -51.64M | -24.36M | -48.22M | -708.99M | -592.46M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings Ltd |
0.01 1.79% |
0.68 | - | 0.77 | 24.95 | 4.04 | 26.33 | 0.19 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
3580 Carmel Mountain Road, San Diego, CA, United States, 92130
877 245 2787
64
| Name | Title | Year Born |
|---|---|---|
| Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder, Pres & Chairman of Directors | 1965 |
| Dr. Zheng Wei Ph.D. | Co-Founder, CEO & Director | 1964 |
| Mr. Steven Chan | Chief Financial Officer | 1972 |
| Mr. Jiang Bian J.D. | Gen. Counsel & Chief Compliance Officer | NA |
| Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC | 1964 |
| Dr. Raul Collazo Ph.D. | VP & Global Head of Medical Affairs | NA |
| Dr. Malinda V. Longphre Ph.D. | Head of US Clinical Operations | NA |
| Dr. Chin Lee M.D., M.P.H. | Chief Medical Officer | 1970 |
| Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder, President & Chairman of the Board of Directors | 1965 |
| Mr. Jiang Bian J.D. | General Counsel & Chief Compliance Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.